$TVTX News
Last published 1d ago
- 1d agoTVTXGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TRAVERE THERAPEUTICS INCEarnings Call TranscriptsOkay, I think we're ready to get started. Thanks, everyone, for joining us again this year for the Guggenheim Healthcare Innovation Conference. And on day two, Vamil Devan, one of the biopharm analysts here, joined up he
- 1w agoTVTXTravere Therapeutics Third Quarter 2026 Earnings Results - TRAVERE THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Travere Therapeutics Third Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Ryan Hayes, Inv
- 1w agoTVTXTravere Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoTVTXTravere Therapeutics to Report Third Quarter 2026 Financial ResultsBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference
- 2w agoTVTXTravere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyBusiness WireFILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual endothelin and
- 1mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its
- 1mo agoTVTXTravere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Business WireTwo-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgANFILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75%
- 1mo agoTVTXKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:...
- 1mo agoTVTXSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - TRAVERE THERAPEUTICS INCEarnings Call TranscriptsHey, everyone. Thanks for joining us for the next Fireside Chat. Very happy to have CEO Eric Dubé and CFO Chris Klein from Travere Therapeutics here for Fireslide. I'm going to kick things over to Chris to give a quick o
- 1mo agoTVTXTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental GlomerulosclerosisBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl
- 1mo agoTVTXTravere Therapeutics Announces Planned Chief Executive Officer TransitionBusiness WireEric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary LeadershipBradley L. Campbell to be Appointed President and CEO Effective December 1,
- 1mo agoTVTXTravere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation ForumBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast
- 2mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement
- 3mo agoTVTXCG 46TH ANNUAL GROWTH CONFERENCE - TRAVERE THERAPEUTICS INCEarnings Call TranscriptsHi, good afternoon everyone. My name is Edward Nash, senior biotech analyst at Canaccord Genuity in the equity research team. It's my pleasure to have with us Trevere Therapeutics. From Trevere, joining us we have Chris
- 3mo agoTVTXTravere Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on
- 3mo agoTVTXTravere Therapeutics Second Quarter 2026 Earnings Results - TRAVERE THERAPEUTICS INCEarnings Call TranscriptsGood morning, and welcome to Travere Therapeutics' second quarter 2026 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference over to Nivi Nera, Vice Presiden
- 3mo agoTVTXTravere Therapeutics Reports Second Quarter 2026 Financial ResultsBusiness WireStrong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of
- 3mo agoTVTXTravere Therapeutics to Report Second Quarter 2026 Financial ResultsBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company will host a
- 3mo agoTVTXKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:...
- 3mo agoTVTXKuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ:TVTX) breached their
- 4mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common
- 4mo agoTVTXTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027Business WireWilliam Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the
- 5mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement
- 5mo agoTVTXTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 CongressBusiness WirePatients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over
- 5mo agoTVTXBusiness Update CallTRAVERE THERAPEUTICS INCEarnings Call TranscriptsGood morning and welcome to Travere Therapeutics Business Update call. Today's call is being recorded. At this time, I would like to turn the conference over to Nivi Naira, Vice President of Corporate Communications and
- 5mo agoTVTXTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney DiseasesBusiness WireCivorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases Civorebrutinib adds
- 5mo agoTVTXTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA NephropathyBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide
- 6mo agoTVTX2026 GLOBAL HEALTHCARE CONFERENCETRAVERE THERAPEUTICS INCEarnings Call TranscriptsWelcome to this, our second day of our Bank of America annual Las Vegas Healthcare Conference. On a very toasty day, I am pleased to invite up here on stage with me, Travere Therapeutics, Eric Dubé, President and CEO, an
- 6mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common
- 6mo agoTVTXTravere Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Health Care Conference Presenting on Wednesday,
- 6mo agoTVTXTravere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible NotesBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes"). The sale of the
- 6mo agoTVTXTravere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible NotesBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 (the "Notes") in an
- 6mo agoTVTXTravere Therapeutics First Quarter 2026 Financial ResultsTRAVERE THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to Trevier Therapeutics' first quarter 2026 financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nera, Vice President,
- 6mo agoTVTXTravere Therapeutics Reports First Quarter 2026 Financial ResultsBusiness WireFILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over year to $105 million FDA approval in FSGS expands total addressable FILSPARI patient
- 6mo agoTVTXTravere Therapeutics to Report First Quarter 2026 Financial ResultsBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call
- 7mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement
- 7mo agoLGNDTVTXLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSGlobeNewswireFILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026
- 7mo agoTVTXTravere Therapeutics FDA Approval of FILSPARI in FSGS Conference CallTRAVERE THERAPEUTICS INCEarnings Call TranscriptsGood afternoon and welcome to the Travere Therapeutics Business Update Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nera, Vice President, Corporate
- 7mo agoTVTXTravere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGSBusiness WireFILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI expands total addressable population to more than
- 8mo agoTVTXTravere Therapeutics Fourth Quarter 2025 Financial ResultsTRAVERE THERAPEUTICS INCEarnings Call TranscriptsGood afternoon and welcome to the Tervir Therapeutics 4th Quarter and Full Year 2025 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Neve
- 8mo agoTVTXTravere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireU.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322
- 9mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement
- 9mo agoTVTXTravere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech SummitBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET. A live webcast
- 9mo agoTVTXTVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover LossesGlobeNewswireBOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ:TVTX) for potential securities law violations. Investors who have lost money in their Travere
- 10mo agoTVTXTravere Therapeutics Provides Corporate Update and 2026 OutlookBusiness WireU.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 Company positioned for successful commercial launch of FILSPARI in FSGS, if approved Pivotal Phase
- 11mo agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on December 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement
- 1y agoTVTXTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on November 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement
- 1y agoTVTXTravere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025Business WireNew late-breaking data from DUPLEX Study show significantly more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan FILSPARI treatment associated with a clinically
- 1y agoTVTXTravere Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting
- 1y agoTVTXTravere Therapeutics Reports Third Quarter 2025 Financial ResultsBusiness WireU.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue for 3Q 2025 was $164.9 million, including U.S. net